

Date: 20/11/2017

FREEDOM OF INFORMATION REQUEST FOI/013738 - Urothelial Cell Cancer / Non small cell lung cancer

How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust:

\* Please note numbers too low to report as would lead to patients potentially being identified

Patient Type	Total number of patients (treated and not treated)	Number currently treated with any active anti-cancer drug treatment (excl. surgery/ radiotherapy only)	Number not treated
All Non-Small Cell Lung Cancer (NSCLC) patients	7	*	*
Patients with NSCLC Stage IIIB**/IV** (Stage 3b/4)	*	*	*

Of the Stage IIIB/IV NSCLC patients, please state the number of patients currently being treated with the following therapies:

Therapy	Number of Stage IIIB/IV NSCLC patients currently treated
Afatinib (Giotrif)	*
Ceritinib (Zykadia)	*
Crizotinib (Xalkori)	*
Erlotinib (Tarceva)	*
Gefitinib (Iressa)	*
Nintedanib + docetaxel	*
Pemetrexed (Alimta) mono or in combination with carboplatin / cisplatin	*
Gemcitabine mono or in combination with carboplatin / cisplatin	*
Atezolizumab (Tecentriq)	*
Nivolumab (Opdivo)	*
Pembrolizumab (Keytruda)	*
Paclitaxel mono or in combination with carboplatin / cisplatin	*
Doxetaxel mono or in combination with carboplatin / cisplatin	*
Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / Cisplatin	*

If your trust does not treat Stage IIIB/IV NSCLC patients and you refer your patients to another trust, please state to which trust patients are referred

The Dudley Group treat our own stage 3B a stage 4 lung cancer patients with the list of chemotherapy agents/TKI's in your attachment. We do not refer these patients outside of the Trust.

The only patients we refer outside of the Trust are stage 1, stage 2 and some stage 3a patients for surgery or radical radiotherapy and Royal Wolverhampton Hospital.

A few patients will be referred to QEH for stereotactic radiotherapy but again these will be early stage disease not stage 3B or stage 4.

**FOI Request re Urothelial Cancer Patients**

How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust:

Patient Type	Total number of patients (treated and not treated)	Number currently treated with any active anti-cancer drug treatment (excl. surgery/ radiotherapy only)	Number not treated
All Urothelial cancer (UCC, transitional carcinoma, TCC) patients	*	*	*
Metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients	*	*	*

Of the metastatic\* or locally advanced\* Urothelial cancer (UCC, transitional carcinoma, TCC) patients, please state the number of patients currently being treated with the following therapies:

Therapy	Number of metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients currently treated
Cisplatinium single agent	*
Cisplatinium in combination with another agent	*
Carboplatinium single agent	*
Carboplatinium in combination with another agent	*
Any other chemo regimen without cisplatinium or carboplatinium	*
Pembrolizumab (Keytruda)	*
Atezolizumab (Tecentriq)	*

If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust patients are referred:

If a patient is on a trial they will be treated elsewhere otherwise bladder cancer is treated at the Trust

---

\*TNM staging for metastatic Urothelial Cancer = Any T, any N, M1

\*TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0